Also trades as: ERIS.BO (BSE) · $vol 0M
ERIS.NS NSE
Eris Lifesciences Limited
1W: -6.7%
1M: -8.5%
3M: -16.9%
YTD: -18.8%
1Y: -29.0%
3Y: +49.5%
5Y: +61.9%
₹1,193.00 ($12.40)
+3.20 (+0.27%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$73.7B
+4.7% ▲
5Y CAGR: +32.0%
Total Liabilities
$34.7B
-7.8% ▼
5Y CAGR: +68.1%
Shareholders Equity
$39.0B
+36.7% ▲
5Y CAGR: +19.9%
Cash & Investments
$673M
-70.5% ▼
5Y CAGR: -12.4%
Total Debt
$23.6B
-4.8% ▼
5Y CAGR: +222.3%
Net Debt
$23.0B
+2.2% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $508M | $560M | $941M | $2.2B | $547M |
| Short-Term Investments | $1.6B | $332M | $12.4B | $50M | $126M |
| Cash & ST Investments | $2.1B | $892M | $13.4B | $2.3B | $673M |
| Net Receivables | $2.1B | $2.9B | $4.2B | $4.6B | $7.3B |
| Inventory | $1.2B | $1.3B | $1.9B | $3.3B | $4.4B |
| Other Current Assets | $667M | $2.3B | $3.5B | $2.0B | $3.0B |
| Total Current Assets | $6.3B | $7.6B | $23.0B | $12.2B | $15.4B |
| Property, Plant & Equip. | $1.9B | $3.8B | $5.3B | $6.6B | $8.8B |
| Goodwill & Intangibles | $7.5B | $22.1B | $38.2B | $46.4B | $44.8B |
| Long-Term Investments | $4.2B | $69M | $157M | $620M | $711M |
| Other Non-Current Assets | $331M | $320M | $664M | $1.5B | $1.5B |
| Total Non-Current Assets | $16.4B | $29.0B | $47.5B | $58.1B | $58.3B |
| Total Assets | $22.7B | $36.7B | $70.5B | $70.3B | $73.7B |
| — Liabilities — | |||||
| Accounts Payable | $1.2B | $1.2B | $3.3B | $3.3B | $3.3B |
| Short-Term Debt | $110K | $1.9B | $20.8B | $6.8B | $13.6B |
| Deferred Revenue | $626M | $1.0B | $209M | $0 | $0 |
| Other Current Liabilities | $95M | -$54M | $1.1B | $3.5B | $3.0B |
| Total Current Liabilities | $2.0B | $4.4B | $25.3B | $13.8B | $20.8B |
| Long-Term Debt | $450M | $6.4B | $6.5B | $17.4B | $9.6B |
| Other Non-Current Liab. | $321M | $605M | $590M | $754M | $916M |
| Total Non-Current Liabilities | $1.6B | $10.0B | $12.9B | $23.8B | $13.9B |
| Total Liabilities | $3.6B | $14.5B | $38.3B | $37.6B | $34.7B |
| — Equity — | |||||
| Common Stock | $136M | $136M | $136M | $136M | $138M |
| Retained Earnings | $18.7B | $21.6B | $25.4B | $27.9B | $34.2B |
| Accumulated OCI | $21M | $30M | $136M | $186M | $126M |
| Total Stockholders Equity | $19.1B | $22.0B | $25.9B | $28.5B | $39.0B |
| Total Liabilities & Equity | $22.7B | $36.7B | $70.5B | $70.3B | $73.7B |
| — Key Metrics — | |||||
| Total Debt | $844M | $8.8B | $27.8B | $24.8B | $23.6B |
| Net Debt | $336M | $8.2B | $26.9B | $22.6B | $23.0B |
| Total Investments | $5.9B | $401M | $12.6B | $670M | $836M |